image credit: Adobe Stock

Lipella Pharmaceuticals, Cook MyoSite Enter Manufacturing Agreement

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company addressing serious diseases with significant unmet need, has entered into a manufacturing collaboration agreement with Cook MyoSite, Inc. to facilitate chemistry, manufacturing, and control (CMC) documentation for Lipella’s drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

Lipella recently released positive topline results from its Phase 2a clinical trial evaluating LP-10 as a drug candidate for hemorrhagic cystitis, a rare and debilitating disease with no FDA approved treatments currently available. The collaboration with Cook MyoSite, a company with 19 years of good manufacturing practice (GMP) manufacturing expertise, is expected to greatly accelerate Lipella’s ability to bring new treatments to patients with unmet needs.

Read More on Contract Pharma